A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
NCT02932410
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
165
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG:
Macitentan
OTHER:
Standard-of-care
Sponsor
Actelion